Tweet
Covaxin, the indigenously developed Covid-19 vaccine, can only be produced in what is classified as a BSL-3 lab. What exactly is a BSL-3 lab? Are there labs that are more secure? How is research carried out at these labs?
The second wave of Covid-19 infections has brought India's healthcare infrastructure to its knees. An unprecedented surge in cases coupled with a sluggish inoculation exercise makes it amply clear that the pandemic is far from over. More than 200 years since the world's first vaccine -- for smallpox -- was developed in 1796, vaccination for Covid-19 is now the top priority of all nations.
At present, two vaccines -- Covishield and Covaxin -- are being produced in India. Covishield (developed by the European company Astrazeneca and University of Oxford) by Pune-based Serum Institute (SII) and the indigenous Covaxin by Hyderabad-based Bharat Biotech.
The second wave of Covid-19 infections has brought India's healthcare infrastructure to its knees. An unprecedented surge in cases coupled with a sluggish inoculation exercise makes it amply clear that the pandemic is far from over. More than 200 years since the world's first vaccine -- for smallpox -- was developed in 1796, vaccination for Covid-19 is now the top priority of all nations.
At present, two vaccines -- Covishield and Covaxin -- are being produced in India. Covishield (developed by the European company Astrazeneca and University of Oxford) by Pune-based Serum Institute (SII) and the indigenous Covaxin by Hyderabad-based Bharat Biotech.